How the MCL treatment landscape is evolving & approaches to different subgroups of patients

David Lewis, MBChB, PhD, FRCPath, Plymouth University, Plymouth, UK, shares insights into the evolving treatment landscape in mantle cell lymphoma (MCL), highlighting the movement of BTK inhibitors into earlier lines. He then discusses various treatment approaches for patients based on data from three trials: TRIANGLE (NCT02858258), ECHO (NCT02972840), and ENRICH (ISRCTN11038174). This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.